Neurology · Pain ManagementRegulatory Approvalregulatorymid-term

FDA Approval Update for FIORICET with Codeine Supplement

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/26/2026, 6:31:30 PM

Assessment confidence: 53% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's acceptance of the supplemental application for FIORICET with Codeine is a significant regulatory milestone that could strengthen Actavis' competitive position in the pain management sector. Pharma strategy teams should closely monitor the approval process and potential market responses from competitors. Regulatory context from FDA (FDA AP — FIORICET W/ CODEINE (SUPPL)) supports the near-term read. Assessment grounded in 8 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and consider potential responses from competitors. The strongest clinical anchor is Evaluation of the Japet.W+ Medical Device for Low Back Pain Management (ClinicalTrials.gov), sub-indication match (pain). In pain, 2 regulatory and 2 competitive items passed relevance filtering for Actavis Labs.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval for Oxycodone Hydrochloride by Novel Labs (Humanexa Signals) — sub-indication match (pain). Secondary pressure from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This approval may enhance Actavis' position in the pain management market, particularly against competitors offering similar formulations.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — FIORICET W/ CODEINE (SUPPL) (FDA). Entity match (actavis labs). The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval decision will be crucial for market entry.

Key Risks

Elevated medium regulatory exposure for Actavis Labs could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, this product could capture additional market share in a competitive landscape, potentially impacting revenue streams for Actavis and its rivals.
Portfolio teams should assess the impact of this approval on market share and consider potential responses from competitors.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval decision and any subsequent market launch timelines.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — FIORICET W/ CODEINE (SUPPL)
FDAmedium relevance
Entity match (actavis labs)
FDA document
View source
FDA AP — FIORICET W/ CODEINE (SUPPL)
FDAmedium relevance
Entity match (actavis labs)
FDA document
View source
FDA AP — CODEINE SULFATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — CODEINE SULFATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Outcome of Treatment With Botulinum toxinA in Patients With Temporomandibular Myofascial Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval for Oxycodone Hydrochloride by Novel Labs
Humanexa Signalsmedium relevance
Sub-indication match (pain)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Grants Approval for Eltrombopag Olamine ANDA208815
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Accepts Supplemental BLA for OCREVUS ZUNOVO by Genentech
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedmedium relevance
Mechanism alignment (IO )
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Actavis Labs
FIORICET with Codeine

Commercial impact

medium

If approved, this product could capture additional market share in a competitive landscape, potentially impacting revenue streams for Actavis and its rivals.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval decision will be crucial for market entry.

What to watch

Monitor for the final approval decision and any subsequent market launch timelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.